Share This Page
Drugs in ATC Class A16
✉ Email this page to a colleague
Subclasses in ATC: A16 - OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS
ATC Class A16 Other Alimentary Tract and Metabolism Products: Market Dynamics and Patent Landscape (2026)
Executive summary: ATC Class A16 is a portfolio category dominated by small-molecule metabolic drugs, enzyme replacements, and niche gastrointestinal metabolism therapies. Patent estates typically split into (1) active-ingredient process and crystalline/solid-state forms, (2) formulation patents (coatings, sustained release, gastro-resistant release, combination tablets), and (3) new therapeutic uses and dosing regimens. Market dynamics are driven by biosimilar-type substitution where biologics/biologics-adjacent products exist, generic entry under Orange Book/ANDA routes, and value-based contracting for chronic-use therapies. Infringement risk clusters around method-of-use claims and solid-state/formulation variants that protect “next generation” product lines after initial API protection expires.
What is driving market dynamics in ATC A16 “other alimentary tract and metabolism products”?
Key market drivers (recurring across A16 segments):
- Chronicity and adherence economics: Many A16 medicines are long-term therapies where payers control spend through formulary placement, step edits, and switching incentives.
- Patent fragmentation across product generations: After initial API patents expire, protection concentrates in formulations, delivery systems, and dosing regimens that can delay or complicate generic substitution.
- Distribution and supply chain constraints: Enzyme and specialized GI products often have manufacturing constraints (stability windows, formulation tolerances), which affects generic launch timing and commercialization.
- Regulatory pathway mix: A16 spans small molecules, enzyme therapies, and combination products, so entry routes vary between ANDA, 505(b)(2), and biologic/BLA-type pathways (where applicable).
- Payer pressure on branded pricing: Brand owners emphasize differentiated pharmacokinetics or patient outcomes where they can support comparative trials or sponsor evidence aligned to payer endpoints.
How does payer contracting influence A16 exclusivity value?
- Formulary leverage: Payers favor market entrants that offer demonstrable cost offsets. Brand strategies typically combine defense (patents) with commercial (rebates, outcomes contracts).
- Switching triggers: Specialty pharmacy programs often create near-term switches at point-of-dispensing after patent/market exclusivity ends, especially when a generic is therapeutically equivalent without clinical differentiation.
Where do payers apply the most scrutiny in A16?
- Per-patient annual cost and dose durability (days-supply and adherence)
- Therapeutic substitution risks where formulation differences change delivery profiles (for example, timing-sensitive GI release)
How is the patent landscape structured for ATC A16 medicines?
Patent estate design patterns in A16:
- Primary composition-of-matter (API) and stereochemistry
- Covers the active ingredient, salts, hydrates, solvates, and stereochemical variants.
- Crystalline and solid-state forms
- Polymorphs, amorphous forms, specific particle size distributions, and solvent-mediated transformations.
- Process and manufacturing
- Improved synthetic routes, purification, and crystallization control steps.
- Formulations and delivery systems
- Enteric coating, gastro-resistant release, controlled release, fixed-dose combinations.
- Method-of-use
- Indication expansions, narrower subpopulations, or optimized dosing regimens.
- Combination and co-administration
- Pairings with other GI/metabolic agents, including “kit” claims and fixed combination tablets/capsules.
Do A16 patents cluster in Orange Book listings?
Yes for small-molecule and 505(b)(2)/ANDA-reliant products, where listings track approved indications and formulations. For products that use non-Orange-Book mechanisms (for example, biologics), the protection perimeter shifts to BLA-related exclusivities and patent thickets rather than Orange Book delisting mechanics.
How many patents typically protect one A16 brand?
In practice, A16 brands often maintain multi-layer estates with:
- Multiple filings per API family
- Follow-on filings for solid state
- Separate formulation/dosage portfolios
- A subset of use patents that survive into the late lifecycle
The actionable takeaway for diligence teams is that the “last listed” Orange Book patents are not the whole story. Many A16 estates include off-Orange-Book continuation claims that still drive Paragraph IV leverage.
Which patent types most delay generic entry in ATC A16?
Most common barriers to generic substitution:
- Enteric/gastro-resistant formulations: Claims on coating composition, thickness ranges, release profiles, and curing processes.
- Solid-state exclusivity: Polymorph/crystal habit claims that require ANDA applicants to show non-infringement or invalidity for specific forms.
- Method-of-use: Narrow dosing intervals, patient subgroups, or outcome-driven dosing strategies.
- Combination tablets/capsules: Co-formulation claims protect physical dosage form and ratio, not just APIs.
How do generic challengers attack A16 patents in Paragraph IV?
Common strategies:
- Non-infringement by using a different solid state form or different dissolution/release characteristics.
- Invalidity based on anticipation/obviousness against earlier disclosures.
- Ineligibility for listed patents if the asserted claims do not cover the marketed product’s relevant features.
When does ATC A16 exclusivity end and what does that mean for launch timing?
Exclusivity concepts that affect launch timing:
- Regulatory exclusivity (data and exclusivity periods) that can block ANDA/505(b)(2) reliance even before patents expire.
- Patent expiration that affects Orange Book “listed” protection.
- Patent litigation + settlement that can extend market entry through agreed launch dates.
What determines the “effective” launch date in A16?
- Whether the brand’s last-to-expire listed patents are:
- formulation/coating claims that are hard to engineer around
- method-of-use claims that create infringement leverage
- Whether Paragraph IV challenges are successful early enough to trigger an immediate launch window.
- Whether generic applicants settle into a carve-out or delayed entry scenario.
How does litigation duration affect A16 market shares?
Even when patents expire on paper, infringement injunction risks and post-expiration damages claims can delay generic entry. In practice, market share shifts often lag behind formal expiration dates.
What is the Orange Book status of key ATC A16 products, and how does it affect generic risk?
ATC A16 is broad, and the Orange Book status varies by specific drug and dosage form. The diligence pattern for business teams is:
- Identify every Orange Book listed patent associated with the approved dosage form.
- Map each patent to claim scope:
- API claim protection vs. formulation/delivery vs. method-of-use.
- Evaluate whether generic applicants can design around without changing bioequivalence outcomes.
Operational risk rule: For A16, formulation patents often drive Orange Book risk more than API patents late in lifecycle because generic developers can source APIs but still must replicate release profile and solid-state behavior.
What generic entry risks exist for ATC A16 products after patent expiration?
Residual risks after “API patent” expiry:
- Solid-state and formulation patents remain active.
- Method-of-use patents can still bar generic launches for the same indication even if the API is no longer protected.
- Combination-specific claims can block fixed-dose generics for particular dosing regimens.
How likely is “authorized generic” or launch mitigation in A16?
- If the brand remains protected by formulation or use patents, brand owners can align with settlement structures or supply arrangements.
- Authorized generics often require IP clearance on the relevant listed patents.
How does ATC A16’s patent strength compare with other gastro-metabolic classes?
Relative characteristics for A16:
- More formulation and solid-state follow-on protection than many purely systemic metabolic products, due to:
- controlled release needs
- GI-specific absorption windows
- dosing regimens that require stable release behavior
- Higher likelihood of multiple patent layers with overlapping expiry dates across:
- dosage strength
- release profile variations
- patient population targeting
Competitive implication: A16 brands typically require deep formulation/IP diligence, not just API expiration tracking.
Which companies hold major patent estates in ATC A16 and who is challenging them?
Company-level mapping requires product-specific Orange Book/Bolar review. Within A16, the patent holder landscape usually mixes:
- Brand originators (API innovators)
- Solid-state/formulation specialists (often assignee-specific continuations)
- Generic challengers (Paragraph IV filers seeking early entry)
- Contract manufacturers (as holders on process and solid-state filings)
Actionable lens for diligence teams: the assignee list on A16 estates tends to show continuity through:
- early-stage R&D assignees for API
- later-stage assignees for formulations/coating/solid state
- continuation-driven assignee changes that can complicate settlement dynamics
What formulation patents are most common in A16: enteric coating, controlled release, and solid-state forms?
Enteric coating and gastro-resistant delivery
Typical claim themes:
- coating polymer blends and weight ratios
- thickness ranges
- curing and plasticizer composition
- dissolution profile targets
Why it matters: ANDA development can match bioequivalence with alternative release profiles, but infringement depends on the claim scope tied to measurable release characteristics.
Controlled release and sustained release
Typical claim themes:
- matrix composition or reservoir structures
- particle size distribution or binder selection
- release kinetics parameters
Crystalline form and polymorph
Typical claim themes:
- X-ray diffraction pattern identifiers
- Raman/IR peaks
- solvent inclusion behavior
- particle size and morphology ranges
Why it matters: solid state engineering is a common generic design-around route, but patents can still capture specific forms or process-induced outcomes.
What method-of-use patents protect A16 and how do they affect indication-specific generics?
Method-of-use patents in A16 tend to:
- narrow the indication to specific GI/metabolic conditions
- define dosing frequency and duration
- cover “patient selection” based on biomarkers or clinical criteria
Generic risk: If a method-of-use claim remains unexpired, generic products may still be blocked from the patented indication or forced into label carve-outs.
Which A16 products face the most litigation-driven delay and what patterns appear in settlements?
Common litigation and settlement patterns in A16:
- early claim construction disputes focused on formulation performance metrics
- injunction threats tied to specific dosage strengths or release profiles
- settlement with a delayed launch date tied to either:
- last-to-expire listed formulation patents
- a mutually agreed entry timeline
- carve-out indications or strengths
Commercial impact: When settlements include carve-outs, payers may steer patients across strengths/doses in ways that preserve brand revenue even after partial generic entry.
How do regulatory designations (505(b)(2), orphan status, pediatric exclusivity) change A16 patent cliffs?
A16 medicines can combine:
- patent protection with regulatory exclusivity that delays generic reliance
- 505(b)(2) pathways that broaden reformulation differentiation and evidence packages
- orphan/pediatric exclusivities in relevant niche indications (case-dependent)
Business effect: the “cliff” date often becomes a layered schedule where:
- patents expire first, but exclusivity blocks ANDA
- exclusivity expires first, but formulation patents still stop approval
A16 market commercialization: what happens to volumes and pricing around patent expiry?
Typical post-expiry trajectory in A16:
- Initial erosion from first authorized generics or challengers
- Price competition stabilizes once multiple entrants are available
- Remaining branded share often persists where:
- formulation differentiation is protected
- payer contracts favor brand
- clinical preference exists due to patient history and tolerability
Key diligence metrics:
- time to first generic listing
- switching rates by payer segment
- pharmacy claim mix by strength/dose
- rebate changes pre- and post-expiry
Key Takeaways
- ATC Class A16 is shaped by formulation and solid-state follow-on patenting more than by early API protection alone.
- Patent estates often protect dose strengths, release profiles, and specific solid-state forms, raising design-around difficulty and extending effective exclusivity.
- Orange Book risk for A16 brands is frequently driven by the last-listed formulation and method-of-use patents, which can block generic entry even after API expiry.
- Market dynamics hinge on payer contracting and switching, so patent cliffs translate into outcomes only after alignment with settlement timing and exclusivity layers.
FAQs
- How do formulation patents in ATC A16 affect ANDA bioequivalence and infringement risk?
- What is the typical strategy for generic applicants to design around A16 solid-state and crystalline form patents?
- Do A16 method-of-use patents prevent generics from receiving full labeling for the same indication?
- How do 505(b)(2) reformulations in A16 change the patent/Orange Book listing cadence for competitors?
- What settlement terms most often delay generic entry for A16 products beyond the last patent expiry date?
References (APA)
- U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
- U.S. Food and Drug Administration. Drug Development and Drug Interactions: Paragraph IV certification basics. https://www.fda.gov
- U.S. Food and Drug Administration. 505(b)(2) Applications. https://www.fda.gov
More… ↓
